Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study

OBJECTIVE: To assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis. METHODS: At baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcutaneous injections of placebo (group 1), golimumab 50 mg (grou...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, Jürgen, Deodhar, Atul, Inman, Robert D, van der Heijde, Désirée, Mack, Michael, Xu, Stephen, Hsu, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329230/
https://www.ncbi.nlm.nih.gov/pubmed/22012970
http://dx.doi.org/10.1136/ard.2011.154799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329230/
https://www.ncbi.nlm.nih.gov/pubmed/22012970
http://dx.doi.org/10.1136/ard.2011.154799

Ejemplares similares